CJ Healthcare said Thursday that it hit record outpatient prescription sales of 20.3 billion won ($18.9 million) for its Anfrade lineup (Ingredient: Sarpogrelate), a chronic arterial occlusive disease treatment, last year.

CJ Healthcare’s Anfrade Tab and Anfrade SR Tab.

The company’s Anfrade lineup -- Anfrade Tab 100 milligram and Anfrade SR Tab 300 milligram – has also become the first product to surpass 20 billion won in the Sarpogrelate ingredient market.

The treatment is used to improve ischemic symptoms such as ulceration, pain, and cold due to chronic arterial occlusion.

The company released Anfrade in 2008 while launching Anfrade SR in 2015. Anfrade’s original drug is Anplag made by Yuhan Corporation. However, the original drug does not include a sustained release (SR) form.

“The company has informed the superiority and prescription option of Anfrade series through various symposiums such as an exclusive symposium and dual symposium with other products,” said Kim Yoo-hyun, Anfrade product manager for CJ Healthcare. “Such efforts became a great influence in the products exceeding 20 billion won in sales.”

The company plans to increase the sales of the drug to more than 30 billion won by 2020, Kim added.

According to Ubist, a medical supplies statistics provider, sarpogrelate ranks third behind clopidogrel and cilostazol in the 760 billion won domestic anti-thrombotic drug market.

Copyright © KBR Unauthorized reproduction, redistribution prohibited